Abstract P068: Soda Consumption and Biomarkers of Cardiovascular Risk in Mexican Women
Background: Soda consumption is associated with type 2 diabetes and cardiovascular disease. Few studies have investigated the relation between sugar-sweetened and artificially sweetened soda consumption and cardiovascular risk biomarkers.
Methods: We evaluated the cross-sectional association between sugar-sweetened and artificially sweetened soda consumption and biomarkers of cardiovascular risk in 874 Mexican women from the Mexican Teachers’ Cohort study. We collected information on habitual consumption (never to ≥6 times per day) of a standard 12 oz serving (1 glass, can, or bottle) of sugar-sweetened and artificially sweetened sodas through a food frequency questionnaire. Plasma concentrations of biomarkers were measured by standard methods. Geometric means were calculated where appropriate.
We used multivariable linear regression models to assess the associations of sugar-sweetened and artificially sweetened soda consumption with CRP, C-peptide, leptin, adiponectin, glucose, HDL-c, LDL-c, total cholesterol and triglycerides. Models were adjusted for age, BMI, physical activity, smoking, menopause, alcohol, family history of coronary heart disease and batches.
Results: Per 12 oz serving/d of sugar-sweetened soda consumption, CRP was 1.07 mg/dL higher (95% CI 1.03 to 1.17), triglycerides were 10.3 mg/dL higher (95% CI 2.2 to 20.4), and adiponectin was 115 ng/mL lower (95% CI -122 to -107). Per 12 oz serving/d of artificially sweetened soda consumption, C-peptide was 0.18 ng/mL lower (95% CI -0.32 to -0.02) (Table 1).
Conclusions: Intake of sugar-sweetened but not artificially sweetened sodas was significantly associated with increased plasma CRP and triglycerides, and decreased adiponectin. Artificially sweetened soda consumption was significantly associated with lower C-peptide.
Author Disclosures: M. Tamez: None. R. López-Ridaura: None. A. Monge: None. I. Romieu: None. S. Rinaldi: None. E. Yunes: None. M. Blanco: None. M. Lajous: B. Research Grant; Significant; Non-restricted investigator-initiated grant from AstraZeneca. C. Other Research Support; Modest; Research support from Suiss Re.
- © 2014 by American Heart Association, Inc.